Ginger: Traditional Use, Constituents and Evidence

My nan kept a knob of fresh ginger wedged between the tea canister and the honey jar, essentially at all times. She didn't call it medicine , she called it "what you have when your stomach's being difficult." That framing stuck with me, probably because it captures something honest about how most of the world has used Zingiber officinale for a very long time: not as a pharmaceutical, but as a plant with a particular character, embedded in food culture and domestic practice across Asia, South Asia, East Africa and eventually Europe and the Pacific.

The science is now substantial enough to be worth taking seriously. It's also messy enough to require some care in how we interpret it.

A brief history of ginger as a phytomedicine

Ginger's documented use in Ayurvedic and Chinese medicine stretches back more than five millennia, with classical texts prescribing the rhizome in dried and fresh forms for entirely different applications , a distinction that remains chemically meaningful today. Sanskrit medical literature references it under the name shunthi (dried) and ardraka (fresh). In Traditional Chinese Medicine it appears as gan jiang and sheng jiang respectively, each assigned different properties within the system's framework.

Arab traders brought it to the Mediterranean in the first century CE; by the medieval period it was one of the most commonly traded spices in Europe, appearing in everything from mulled wine recipes to plague remedies in the 14th century. This dual culinary and medicinal identity , unusual even by spice standards; has complicated efforts to study it systematically, because the form, dose and preparation vary so widely across traditions.

If you want to read the primary material, the 1597 herbal by John Gerard remains a surprisingly readable entry point. He describes the "hot and moyst" temperament of ginger in terms of Galenic humoral medicine, which is obviously not how we'd frame it now, but the applications he lists align fairly closely with the ones that appear in clinical trial registrations today. That kind of continuity across four centuries is worth paying attention to.

Key constituents: gingerols, shogaols and beyond

Fresh ginger rhizome contains a family of phenolic compounds collectively called gingerols, with [6]-gingerol being the most abundant and the most studied. When ginger is dried or heat-processed, gingerols undergo dehydration to form shogaols, particularly [6]-shogaol; which appear more potent in several laboratory assays. This is not a trivial distinction; the constituent profile of a standardised dried extract differs meaningfully from fresh juice or raw root powder.

Other biologically characterised constituents include:

• Paradols, reduction products of shogaols, present in dried preparations
• Zingerone, forms during cooking; structurally related to vanillin
• Gingerdiones and related diarylheptanoids
• A volatile oil fraction containing zingiberene, bisabolene, and beta-caryophyllene; a sesquiterpene also found in cannabis and studied in its own right for interactions with CB2 receptors

That volatile fraction connects ginger, in a modest way, to cannabinoid pharmacology. Beta-caryophyllene has been characterised as a dietary CB2 receptor agonist in preclinical work, though whether this is clinically relevant at the concentrations present in typical ginger preparations is a separate and still-open question. Worth knowing about; not worth overstating.

The terpene content of ginger essential oil also includes compounds like bisabolol and related sesquiterpene alcohols, which adds to the chemical complexity any rigorous study needs to account for.

What the research shows, and where it stops short

The honest short version is: there's a reasonable body of human trial data, most of it underpowered, and some consistent signals in specific contexts that warrant further investigation. The preclinical literature (cell cultures, rodent models) is extensive and often mechanistically interesting; the jump to established clinical effect in humans is frequently overstated in secondary sources.

The most replicated signal in controlled human trials involves nausea, particularly pregnancy-related nausea and post-operative nausea; but it's worth being specific about what "replicated" means here. A 2014 Cochrane-style systematic review found evidence rated as "low to moderate quality" due to small sample sizes, inconsistent dosing and variable preparation types. The 2019 Cochrane review on interventions for nausea and vomiting in early pregnancy (Jennings & Krywko, updated 2022) includes ginger among the examined interventions and notes that evidence remains limited by methodological heterogeneity. That's not a dismissal, it's a descriptor of the evidence tier, and it matters for anyone trying to distinguish mechanistic plausibility from established efficacy.

Mechanistic research has characterised gingerols and shogaols as inhibitors of 5-HT3 receptors (serotonin receptors involved in the emetic reflex) and has identified interactions with TRPV1 channels, the same receptor family activated by capsaicin. There's also laboratory-level investigation into COX-1 and COX-2 pathway modulation, which is why ginger appears regularly in research on inflammatory processes, though the clinical translation of these findings remains an active area of study rather than settled science.

I'd argue the popular science literature has not been careful enough to distinguish "this compound modulates this pathway in a petri dish" from "this preparation produces a clinically meaningful effect in a specific population." They're related claims, but they're not the same claim.

Phytomedicine framing and the standardisation problem

One reason the evidence picture is difficult to read is the standardisation problem. Ginger products on the Australian market range from raw dried root powder in capsules to hydroethanolic extracts standardised to a defined percentage of gingerols. These are not interchangeable, and a trial using one preparation tells us limited things about another.

This is relevant to how we read the literature as a phytomedicine, and it's relevant to Australian regulatory categorisation. The Therapeutic Goods Administration lists many ginger-containing products on the Australian Register of Therapeutic Goods (ARTG) as Listed medicines; the lower-evidence tier that requires manufacturers to hold evidence supporting their claims but does not require pre-market efficacy review by the TGA itself. Listed medicines carry an "AUST L" number. Those with higher evidence review receive an "AUST R" registration.

Importantly, any therapeutic claim made on a Listed medicine product must be drawn from the TGA's Permitted Indications list or be supported by evidence held by the sponsor. The phrase "supports healthy digestion" is a permitted low-level claim; a claim to treat a diagnosed condition would move the product into a different regulatory category entirely. This distinction matters because it shapes what consumers can reasonably infer from labelling. If you're reading a ginger product label in Australia, understanding the AUST L / AUST R distinction, and what Good Manufacturing Practice requirements apply, gives you a more grounded framework for evaluating it.

A standardised extract requires the manufacturer to demonstrate batch-to-batch consistency in active constituent levels. Many ginger products on shelf are not standardised extracts in this sense. That's neither automatically good nor bad, but it is a variable worth noting when comparing studies or products.

Pharmacokinetics: a brief note

Gingerols and shogaols are absorbed primarily in the small intestine and undergo hepatic metabolism; the first-pass metabolism effect means oral bioavailability of specific constituents is substantially lower than the concentration in the raw plant material. Bioavailability studies on [6]-gingerol in humans are limited, and the pharmacokinetics of the shogaol metabolites (notably [6]-shogaol's conversion to sulfonate conjugates) are still being characterised. This is worth flagging for anyone trying to interpret dose-response relationships in the clinical literature, the dose on the label is not the plasma concentration.

A note on ginger versus controlled or restricted botanicals

Ginger carries no scheduling under the Poisons Standard and requires no Special Access Scheme pathway, contrast this with, say, kava (Piper methysticum), which has import controls under Australian Border Force regulations and a complex history with the TGA around therapeutic product approvals. Or compare the pathway required for any cannabis-derived constituent, where even low-THC preparations require Special Access Scheme or Authorised Prescriber approval as Schedule 4 or Schedule 8 medicines. Ginger sits firmly in the open-access category; food, complementary medicine, or research material, which is one reason the clinical literature on it exists at all, without the access barriers that slow research on more tightly scheduled botanicals.

The terpene crossovers I mentioned earlier, beta-caryophyllene, bisabolol and related compounds appearing in both ginger's volatile fraction and in cannabis essential oil; are a reminder that plant chemistry doesn't respect the regulatory categories we build around it. Understanding both is useful context for anyone reading about the broader entourage effect literature in cannabis research.

Anyway. Nan was not wrong about the ginger. She was just operating from five thousand years of empirical observation rather than a randomised controlled trial, and honestly, that's a decent starting point, so long as we hold the next layer of scrutiny in the same hand.

Sources

• Listed Medicines Evidence Guidelines, Therapeutic Goods Administration (TGA)
• Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: a systematic review; NCBI / PubMed
• Zingiber officinale: a review of its biological activity, NCBI PMC
• Interventions for nausea and vomiting in early pregnancy, Cochrane Library

, Naomi Ellison, Botanical & phytomedicine writer

]]>